Targeted Therapy in Translational Cancer Research: Translational Oncology

In the last decade, emergent technologies have enhanced our understanding of genomic, transcriptional, proteomic, epigenetic, and immune mechanisms in carcinogenesis. This improved understanding has enabled the development of targeted cancer therapies and personalized management, and transformed conventional treatment paradigms. It has provided the framework for the discovery of new targets, for validation of novel agents, for combination therapies predicated upon scientific rationale, and for clinical trials that have already markedly improved the prognosis and outcome of patients with cancer.

Over 37 chapters this volume of Translational Oncology series, Targeted Therapy in Translational Cancer Research

• Introduces the cutting-edge 'bench to bedside and back' breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer
• Provides a comprehensive overview of recent developments in our understanding of tumor biology and describes current state-of-the-art anticancer therapy, as well as the most promising areas of translational research and targeted therapy
• Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine
• Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities

We are on the threshold of translating discoveries in cancer biology into unprecedented durable responses and improved clinical outcomes in the majority of patients with cancer. In this unique time in history, the discovery of novel therapeutic approaches targeting the molecular basis of cancer will allow for implementation of precision medicine, with the promise of potentially curative, well tolerated, therapies. Targeted Therapy in Translational Cancer Research was written to increase the awareness and access of basic and clinical researchers, caregivers, and patients alike to cutting-edge "bench to bedside and back" breakthroughs, which have transformed the diagnosis, prognosis, and treatment of cancer.

The expert editor team and contributing authors provide an insightful overview to the novel therapeutic approaches targeting the molecular basis of cancer and allowing for the growth of precision medicine. This title is an essential resource for clinical and research oncologists and trainees, pharmacologic research and development professionals, biomedical scientists, and allied oncology professionals.

Translational Oncology Series
Series Editors
ROBERT C. BAST, MD
Vice President for Translational Research
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

MAURIE MARKMAN, MD
Senior Vice President for Clinical Affairs
Cancer Treatment Centers of America
Clinical Professor of Medicine
Drexel University College of Medicine
Philadelphia, PA, USA

ERNEST HAWK, MD, MPH
Vice President, Division of OVP, Cancer Prevention and Population Sciences
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

Other volumes in the Translational Oncology Series
Cancer Gene Therapy by Viral and Non-viral Vectors
Edited by Malcolm Brenner and Mien-Chie Hung
978-1-118-50162-7